Bio­gen yanks its Aduhelm ap­pli­ca­tion in Cana­da, days af­ter cel­e­brat­ing the drug's 1-year an­niver­sary in the US

Add Cana­da to the list of coun­tries where Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm isn’t want­ed by health of­fi­cials.

The biotech an­nounced on Thurs­day that it’s pulling ad­u­canum­ab’s new drug sub­mis­sion (NDS) in Cana­da af­ter the coun­try’s health agency in­di­cat­ed that “the da­ta pro­vid­ed would not be suf­fi­cient to sup­port a mar­ket­ing au­tho­riza­tion.”

The news comes just a cou­ple of months af­ter Bio­gen pulled ad­u­canum­ab’s ap­pli­ca­tion in Eu­rope, where reg­u­la­tors re­ject­ed it late last year — and al­most a year to the date since the drug won its high­ly dis­put­ed ac­cel­er­at­ed ap­proval in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER